# Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Source: https://onco.cc/trials/nct03435796/  
OnCo record `nct03435796` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Gene-modified (GM) T cell therapy in advanced solid tumours, run by Celgene, now recruiting.

## Summary

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells is a phase 2/3 interventional study registered as NCT03435796 by Celgene, with 1541 participants planned, started 2018-07-19 and due to reach its primary completion in 2036-11-30. Interventions recorded: Gene-modified (GM) T cell therapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03435796
- Phase: 2/3
- Setting: Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
- Sponsor: Celgene
- Enrolled: 1541

## Sources

- ClinicalTrials.gov NCT03435796: https://clinicaltrials.gov/study/NCT03435796

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)

---
JSON: https://onco.cc/api/v1/entities/nct03435796.json